Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M G Manz

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II studyW Brugger, J Hirsch, F Grünebach, et al.
Leukemia|July 16, 2016
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratioJ Versluis, F E M In 't Hout, R Devillier, et al.
Leukemia|November 28, 2014
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 yearsJ J Cornelissen, J Versluis, J R Passweg, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 3, 2004
Rituximab consolidation after high-dose chemotherapy and autologous blood stem cell transplantation in follicular and mantle cell lymphoma: a prospective, multicenter phase II studyW Brugger, J Hirsch, F Grünebach, et al.
Leukemia|July 16, 2016
Comparative value of post-remission treatment in cytogenetically normal AML subclassified by NPM1 and FLT3-ITD allelic ratioJ Versluis, F E M In 't Hout, R Devillier, et al.
Leukemia|November 28, 2014
Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 yearsJ J Cornelissen, J Versluis, J R Passweg, et al.
Pageof 2